- Home
- ATEN vs PVLA Comparison
ATEN vs PVLA Comparison
Compare ATEN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEN | PVLA |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATEN | PVLA |
|---|---|---|
| Price | $28.12 | $119.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $26.33 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.0M | 182.0K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $235,429,000.00 | N/A |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $10.82 | $104,350.18 |
| P/E Ratio | $163.82 | ★ N/A |
| Revenue Growth | ★ 2.36 | N/A |
| 52 Week Low | $16.52 | $20.20 |
| 52 Week High | $28.59 | $151.18 |
Technical Indicators
Market Signals| Indicator | ATEN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 46.96 |
| Support Level | $17.08 | $109.68 |
| Resistance Level | $28.39 | $135.23 |
| Average True Range (ATR) | 0.99 | 7.73 |
| MACD | -0.11 | -0.90 |
| Stochastic Oscillator | 92.88 | 44.92 |
Price Performance
Historical ComparisonAbout ATEN A10 Networks Inc.
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.